Vor Bio Presents Data on AML Therapy at ASH 2024 Annual Meeting
Vor Bio Presents Data on AML Therapy at ASH 2024 Annual Meeting
Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg. The data, which was presented in a poster at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 8th, demonstrated durable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of improved relapse free survival compared to published high-risk AML comparators.
Vor Bio (纳斯达克:VOR)是一家临床阶段的电芯和基因工程公司，今天宣布了其正在进行的VBP101研究的更新临床数据，该研究针对接受了trem-cel治疗后再接收Mylotarg的复发/难治性急性髓系白血病患者。该数据在2023年12月8日星期日的美国血液学会（ASH）年会上以海报形式展示，显示出持久的移植、对Mylotarg靶点毒性的保护、Mylotarg治疗窗口的扩大，以及与已发布的高风险急性髓系白血病对照组相比，早期改善复发无生存的证据。
